Head-to-head · Cost-Efficiency Index
StackMD vs VevaRX
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
StackMD
Shoppers price-scanning for the lowest advertised entry point, who should confirm true dose-adjusted cost before signing up.
Visit StackMDVevaRX
Readers in one of the 36 states it names who will confirm the charge in writing before submitting an intake.
Visit VevaRXThe verdict
StackMD and VevaRX tie on the Cost-Efficiency Index at 60/100, so neither wins outright on the numbers. For most shoppers we'd start with StackMD (ranked #247, a hair above #251) — Shoppers price-scanning for the lowest advertised entry point, who should confirm true dose-adjusted cost before signing up. But VevaRX is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs StackMD.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | StackMD | VevaRX |
|---|---|---|
| Cost-Efficiency Index | 60/100 | 60/100 |
| Semaglutide / mo | Not disclosed | $189/month month-to-month (the same page also prints $167/month and a $467 three-month total) |
| Tirzepatide / mo | Not disclosed | $155.67/mo equivalent — VevaRX bills $467 every three months on a three-month minimum and publishes no monthly plan |
| Semaglutide / yr (modeled) | — | $2,268 |
| Tirzepatide / yr (modeled) | — | $1,860 |
| Coverage | All 50 states | 36 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #247 | #251 |
StackMD
60/100Where the value is
- Low advertised entry price ($99/mo) for both semaglutide and tirzepatide
- Clear FDA-compounding disclaimer shown up front
- Distinct national telehealth brand (separate from the similarly-named Long Island clinic)
The tradeoffs
- Identical $99 headline for both drugs strongly suggests a lowest-dose teaser, not full treatment pricing
- No dose tiers, medical director, pharmacy name, states list, or LegitScript status could be confirmed
VevaRX
60/100Where the value is
- Enumerates the 36 states it serves by name rather than making an unqualified nationwide claim
- States what the tirzepatide price covers — the treatment, the supplies, the provider visit and two-to-three-day shipping
- Publishes a monthly semaglutide option alongside the quarterly plan, which its tirzepatide program does not offer
The tradeoffs
- The semaglutide page carries four prices, two of which belong to tirzepatide: $189 a month, $399 for three months, $167 a month and a $467 total
- The tirzepatide page's own arithmetic is wrong — it calls $467 over three months "equivalent to $149 per month", when it is $155.67, a figure the semaglutide page states correctly
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.